resomelagon
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2019 (NCT04004429)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Melanocortin receptor 1ACTIVATOR
MC1R activator
- Melanocortin receptor 3ACTIVATOR
MC3R activator
Chemistry & pharmacology
Loading structure…
SMILES
N=C(N)N/N=C/C=C/c1cccn1-c1ccccc1[N+](=O)[O-]- Mol. weight
- 298.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315047 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06671054 | Phase 2 | Oct 1, 2024 | Nordic Bioscience, SynAct Pharma Aps |
| NCT05604885 | Phase 2 | Nov 30, 2022 | Nordic Bioscience, SynAct Pharma Aps |
| NCT05516979 | Phase 2 | Sep 26, 2022 | Nordic Bioscience, SynAct Pharma Aps |
| NCT04456816 | Phase 2 | Aug 31, 2020 | Aarhus University, SynAct Pharma Aps |
| NCT04004429 | Phase 2 | Jul 1, 2019 | Aarhus University, SynAct Pharma Aps |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SynAct Pharma Aps | For profit | 5 | 5 | 1 | 2019 |
| Nordic Bioscience | For profit | 3 | 0 | 1 | 2022 |
| Aarhus University | Academic/Hospital | 2 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1